{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061101","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.766736+00:00","generated_at":"2026-06-08T10:32:36.074598+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024","bullets":["Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.","Cash and securities $43.4M (Sept 30, 2023), down from $53.4M (June 30, 2023); runway into 2025.","Phase 1a data for SZN-043 and SZN-1326 expected Q1 2024; Phase 1b studies to initiate in 2024.","Two new USPTO patents granted (Nos. 11/746,150 and 11/773,171) for SZN-1326 and SWAP technology.","Boehringer Ingelheim partnership: potential $10M milestone in 2024 upon candidate nomination."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061101","json":"https://secwatch.observer/filing/0000950170-23-061101.json","markdown":"https://secwatch.observer/filing/0000950170-23-061101.md","text":"https://secwatch.observer/filing/0000950170-23-061101.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/0000950170-23-061101-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/srzn-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:32:36.074598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bebc8564a01003f4865e9a5d1a210a676c6d799d","claim":"Surrozen, Inc./DE reported the third quarter ended September 30, 2023 results: net income $10.4 million.","evidence_excerpt":"Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017023061101/0000950170-23-061101-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}